

# Norihiro Kogame

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/346920/publications.pdf>

Version: 2024-02-01

45  
papers

1,422  
citations

516710

16  
h-index

345221

36  
g-index

45  
all docs

45  
docs citations

45  
times ranked

1769  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The.</i> 2018, 392, 940-949.	13.7	555
2	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. <i>European Heart Journal</i> , 2019, 40, 2595-2604.	2.2	93
3	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2064-2075.	2.9	71
4	Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2251-2262.	2.9	70
5	Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 119.	2.4	65
6	The Impact of Coronary Physiology on Contemporary Clinical Decision Making. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1617-1638.	2.9	60
7	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	6.1	49
8	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 259-270.	2.9	46
9	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020, 295, 45-53.	0.8	36
10	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1877-1886.	2.8	33
11	Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. <i>Expert Review of Medical Devices</i> , 2019, 16, 211-228.	2.8	27
12	Impact of post-procedural minimal stent area on 2-year clinical outcomes in the SYNTAX II trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E225-E234.	1.7	26
13	Feasibility of planning coronary artery bypass grafting based only on coronary computed tomography angiography and CT-derived fractional flow reserve: a pilot survey of the surgeons involved in the randomized SYNTAX III Revolution trial. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 29, 209-216.	1.1	24
14	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	2.8	23
15	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	1.7	19
16	A Randomized Trial Evaluating Online 3-Dimensional Optical Frequency Domain Imaging-Guided Percutaneous Coronary Intervention in Bifurcation Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009183.	3.9	19
17	Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008737.	3.9	17
18	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 634-646.	2.9	17

#	ARTICLE	IF	CITATIONS
19	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e1090-e1098.	3.2	16
20	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009177.	3.9	15
21	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 930-943.	3.3	14
22	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1125-1139.	3.3	14
23	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006660.	2.2	11
24	A Prospective Multicenter Randomized Trial to Assess the Effectiveness of the MagicTouch Sirolimus-Coated Balloon in Small Vessels: Rationale and Design of the TRANSFORM I Trial. <i>Cardiovascular Revascularization Medicine</i> , 2021, 25, 29-35.	0.8	10
25	Impact of stent length and diameter on 10-year mortality in the <sc>SYNTAXES</sc> trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E379-E387.	1.7	10
26	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 222-230.	3.0	7
27	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 22-30.	3.0	7
28	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1189-1198.	1.5	6
29	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	1.7	6
30	Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 931-945.	5.0	6
31	Predicting 2-year all-cause mortality after contemporary <sc>PCI</sc>: Updating the logistic clinical <sc>SYNTAX</sc> score. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1287-1297.	1.7	6
32	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 16, 634-644.	3.2	6
33	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1833-1840.	1.6	5
34	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E516-E526.	1.7	5
35	Diagnostic concordance and discordance between angiography-based quantitative flow ratio and fractional flow reserve derived from computed tomography in complex coronary artery disease. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 336-342.	1.3	5
36	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. <i>Canadian Journal of Cardiology</i> , 2021, 37, 122-130.	1.7	4

#	ARTICLE	IF	CITATIONS
37	A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study. <i>American Heart Journal</i> , 2021, 239, 19-26.	2.7	4
38	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	3.7	4
39	Cracking (the code of) coronary artery calcification to win the last battle of percutaneous coronary intervention: still in the middle of a rocky road. <i>European Heart Journal</i> , 2020, 41, 797-800.	2.2	3
40	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 918-929.	3.3	3
41	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. <i>Canadian Journal of Cardiology</i> , 2020, 36, 747-755.	1.7	2
42	Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model. <i>Circulation Journal</i> , 2019, 83, 556-566.	1.6	1
43	Two years clinical outcomes with the state-of-the-art PCI for the treatment of bifurcation lesions: A sub-analysis of the SYNTAX II study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 10-17.	1.7	1
44	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. <i>Atherosclerosis</i> , 2020, 303, 1-7.	0.8	1
45	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 565-575.	1.5	0